Safety reporting and sponsor blinding on every HCP interview
Every transcript is screened for adverse events, with reports to your drug-safety team within 24 hours and a full reconciliation at study end, in every interview language. Studies are sponsor-blinded by default and de-identified to the HIPAA Safe Harbor standard, with a BAA available.
What is adverse-event reporting in market research with Carevoices?
Adverse-event reporting in market research means catching any side effect, product complaint or other safety information a clinician raises during a study, and passing it to the sponsor's safety team within a set window. On a Carevoices study that window is 24 hours, and it runs alongside sponsor blinding and HIPAA Safe Harbor de-identification, so one process answers your PV, compliance and privacy reviewers.
Safety reporting your PV team can sign off
Every study ships with the safety record your drug-safety or complaint-handling team needs, alongside the research itself.
Reports within 24 hours
Each adverse event or product complaint a clinician raises reaches your named safety contact within 24 hours, in every interview language.
A study-end reconciliation
A full reconciliation at study end, so your PV team can confirm every report against the interviews that ran.
A blinded study record
Invitations, screeners, consent and the interview never name the commissioning company, unless unblinded work is agreed in the study plan.
De-identified deliverables
Transcripts and findings de-identified to the HIPAA Safe Harbor standard, with no audio or video shared by default.
What your safety team gets
On by default, in every interview language. Your drug-safety or complaint-handling contact is named in the study plan.
Safety reporting
Every transcript is screened for adverse events, with reports to your drug-safety team within 24 hours and a full reconciliation at study end, in every interview language. For medical devices, product complaints and potential adverse events raised in an interview are reported to your complaint-handling team within 24 hours, with a reconciliation at study end.
Sponsor blinding
Sponsor-blinded by default: participants never learn who commissioned the study. Invitations, screeners, consent and the interview never name the commissioning company. Participant consent includes the adverse-event disclosure the market-research codes require.
De-identified results
Every deliverable is de-identified to the HIPAA Safe Harbor standard, with all 18 identifiers removed. Insights deliverables never include participant identities, and no audio or video is shared by default. Contact details reach the sponsor’s drug-safety team only if the clinician agrees to adverse-event follow-up; any unblinded work is agreed in the study plan.
Data protection
HIPAA-enabled, with a BAA available. SOC 2 Type II compliant. Run in line with the EphMRA, BHBIA and Insights Association codes of conduct.
From brief to a reconciled safety record
A proposal within 24 hours of your brief, and results in 1–2 weeks from plan approval.
Safety route agreed
A proposal within 24 hours of your brief. The study plan you approve names your drug-safety or complaint-handling contact.
Every transcript screened
Each transcript is screened for adverse events, product complaints and other safety information, in the language the interview ran in.
Safety report sent
A report reaches your drug-safety team, or your complaint-handling team for a device, within 24 hours of the interview.
Reconciled, de-identified results
A full reconciliation arrives with the Safe Harbor de-identified transcripts, in 1–2 weeks from plan approval. Whether a report meets a regulatory obligation remains your determination.
Where safety review matters most
Message Testing
HCP reactions to claims and messages, where efficacy and safety come up most often.
→Advisory Research
KOL and advisory work with fair-market-value honoraria, paid in compliance with the Sunshine Act.
→Concept Testing
Concept and stimulus reviews with verified clinicians, sponsor-blinded and de-identified.
→Carevoices vs. general AI interview tools vs. traditional fieldwork
| Dimension | Carevoices | General AI interview tool | Traditional HCP fieldwork |
|---|---|---|---|
| Adverse-event screening | Every transcript, every interview language | Left to the sponsor | Through the vendor's PV process |
| Reporting window | Within 24 hours, reconciled at study end | Not defined | Varies by vendor |
| Sponsor blinding | By default | Set up by the sponsor | Varies by vendor |
| De-identification | HIPAA Safe Harbor, all 18 identifiers | Raw transcripts and recordings | Varies by vendor |
| Participants | Identity, license and NPI verified | Consumer or self-attested panels | Panel-dependent |
Frequently asked questions
Field HCP research your PV team signs off on
Send a brief and get a proposal within 24 hours. Your drug-safety and compliance reviewers are welcome on the call.
Related resources
Built for these teams
Deep-dive guides covering this topic from strategy to execution.
Study types with the same safety posture
Practical frameworks and platform-specific guides for teams ready to act.
Compliance reference reading
Reference deep-dives on methodology, best practices, and applied research.
How Carevoices compares on compliance
Side-by-side comparisons with competing platforms and approaches.
More platform capabilities
The platform features that power this type of research.